Asset profile
Dipraglurant (ADX48621)
Small molecule
Evidence outlook · registrational
Parkinson's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT01336088: The study randomized 83 participants to dipraglurant or placebo and masked both participants and investigators. Its primary endpoint was the number of patients with abnormal safety and tolerability assessments over four weeks, but no primary endpoint results or statistical comparison are posted, preventing confirmation of a favorable result.
The registered primary objective was safety and tolerability (met, no major safety concerns); the dyskinesia reduction shown was a prespecified secondary efficacy measure.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.